

123. (Amended) The conjugate of claim 12, wherein the glycoprotein has the sequence of human erythropoietin modified by the rearrangement of at least one glycosylation site.

Please add the following new claims:

191. (New) A conjugate comprising an erythropoietin glycoprotein having a free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to a poly(ethylene glycol) groups of the formula $-\text{CO}-(\text{CH}_2)_x-(\text{OCH}_2\text{CH}_2)_m-\text{OR}$ by the $-\text{CO}$ of said poly(ethylene glycol) group forming an amide bond with said amino groups; wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 900; and m is chosen so that the molecular weight of the conjugates minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.

202. (New) The conjugate of claim 191 of the formula:



wherein m, x and R are as above

and P is the residue of the glycoprotein without the n amino group(s) which form amide linkage(s) with the poly(ethylene glycol) group(s).

203. (New) The conjugate of claim 5 wherein x is 3.

7
81. (New) The conjugate of claim 63 wherein said molecular weight is from about 20kDa to about 40kDa.

8
91. (New) The conjugate of claim 64 wherein said molecular weight is about 30kDa.
